Use of recombinant tissue-plasminogen activator for aortic thrombolysis in a hypoproteinemic dog

Journal of the American Veterinary Medical Association

Volumn 212, Issue 4, 1998, Pages 539-543

  Clare, Amy C ^a,c   Kraje, Brian J ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b Knoxville Pet Emergency Clinic   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALTEPLASE; CREATINE KINASE; DEFEROXAMINE MESYLATE; DIPHENHYDRAMINE; FRESH FROZEN PLASMA; PROTEIN; RINGER LACTATE SOLUTION;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA THROMBOSIS; ARTICLE; DOG; FIBRINOLYTIC THERAPY; HYPERESTHESIA; HYPOPROTEINEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARALYSIS;

ANIMALS; ANTITHROMBIN III DEFICIENCY; AORTA; DOG DISEASES; DOGS; HYPOPROTEINEMIA; MALE; PLASMINOGEN ACTIVATORS; PROTEIN-LOSING ENTEROPATHIES; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

ANIMALIA; CANIS FAMILIARIS;

EID: 0032519279     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Van Winkle TJ, Hackner SG, Liu SM. Clinical and pathological features of aortic thromboembolism in 36 dogs. J Vet Emerg Crit Care 1993;3:13-21.
2. Suter PF, Fox PR. Peripheral vascular disease. In: Ettinger SJ, Feldman EC, eds. Textbook of veterinary internal medicine. 4th ed. Philadelphia: WB Saunders Co, 1995;1068-1071.
3. Welles EG. Antithrombotic and fibrinolytic factors: a review. Vet Clin North Am Small Anim Pract 1996;26:1111-1127.
4. Ramsey CC, Burney DP, Macintire DK, et al. Use of streptokinase in four dogs with thrombosis. J Am Vet Med Assoc 1996; 209:780-785.
5. Doweiko JP, Bistrian BR. The effect of glycosylated albumin on platelet aggregation. J Parenter Enteral Nutr 1994;18:516-520.
6. Becker RC. Recombinant t-PA and platelet activity. Cleve Clin J Med 1990;57:537-541.
7. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990;322:33-42.
8. Bertolino G, Noris P, Previtali M, et al. Platelet function after in vivo and in vitro treatment with thrombolytic agents. Am J Cardiol 1992;69:457-461.
9. Terres W, Umnus S, Mathey DG, et al. Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates. Cardiovasc Res 1990;24:471-477.
10. Lonsdale RJ, Berridge DC, Earnshaw JJ, et al. Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis. Br J Surg 1992; 79:272-275.
11. Bick RL, Pegram M. Syndromes of hypercoagulability and thrombosis: a review. Semin Thromb Hemost 1994;20:109-132.
12. Kaplan AJ, Peterson ME, Kemppainen RJ. Effects of disease on the results of diagnostic tests for use in detecting hyperadrenocorticism in dogs. J Am Vet Med Assoc 1995;207:445-451.
13. Jensen AL, Iversen L, Koch J, et al. Evaluation of the urinary cortisol:creatinine ratio in the diagnosis of hyperadrenocorticism in dogs. J Small Anim Pract 1997;38:99-102.
14. Hammer AS. Thrombocytosis in dogs and cats: a retrospective study. Comp Haematol Int 1991;1:181-186.
15. Gulba DC, Bode C, Runge MS, et al. Thrombolytic agents - an overview. Ann Hematol 1996;73:S9-S27.
16. Comerota AJ, Cohen GS. Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and drugs available. Can J Surg 1993;36:342-348.
17. Agnelli G. Rationale for bolus t-PA therapy to improve efficacy and safety. Chest 1990;97:161S-167S.
18. Topol ET, Agnelli G. Strategies for administration of tissue plasrmnogen activator. Mol Biol Med 1991;8:219-234.
19. Grines CL. Thrombolytic, antiplatelet, and antithrombotic agents. Am J Cardiol 1992;70:181-261.
20. Klabunde RE, Burke SE, Henkin J. Enhanced lytic efficacy of multiple bolus injections of tissue plasminogen activator in dogs. Thromb Res 1990;58:511-517.
21. Longridge DJ, Follenfant MJ, Ford AJ. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion. Cardiovosc Res 1991;25:184-191.
22. Ward AS, Andaz SK, Bygrave S. Peripheral thrombolysis with tissue plasminogen activator. Arch Surg 1994;129:861-865.
23. Buckenham TM, George CD, Chester JF et al. Accelerated thrombolysis using pulsed intra-thrombus recombinant human tissue type plasminogen activator (rt-PA). Eur J Vasc Surg 1992;6: 237-240.
24. White HD. Comparative safety of thrombolytic agents. Am J Cardiol 1991;67:30E-37E.
25. Califf RM, Fortin DF, Tenaglia AN, et al. Clinical risks of thrombolytic therapy. Am J Cardiol 1992;69:12A-20A.
26. Schweizer J, Altmann E, Stosslein F et al. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Eur J Radiol 1996; 22:129-132.
27. Rochat MC. An introduction to reperfusion injury. Compend Contin Educ Pract Vet 1991;13:923-930.
28. Voest EE, Vreugdenhil G, Marx JJM. Iron-chelating agents in non-iron overload conditions. Ann Intern Med 1994;120: 490-499.
29. Grauer GF, Rose BJ, Toolan L, et al. Effects of low-dose aspirin and specific thromboxane synthetase inhibition on whole blood platelet aggregation and adenosine triphosphate secretion in healthy dogs. Am J Vet Res 1992;53:1631-1635.